Regenerative Medicine

A new partnership introduces PBSerum®, a biologically inspired enzyme treatment, aiming to redefine skin quality in the multi-billion dollar aesthetics market.

With 35+ years of orthopedic sales experience, Thurman Ballard joins Tetrous to drive adoption of its groundbreaking bone-to-tendon healing technology.

Biotech firm Humacyte raises $20M to accelerate sales of its FDA-approved Symvess® and fund crucial trials for new hemodialysis applications.

With promising clinical data for its heart disease treatments, Lexeo Therapeutics aims to capture investor attention at the upcoming Leerink conference.

enGene hits the road for key investor conferences, showcasing a promising non-viral gene therapy for a tough-to-treat bladder cancer. Will it succeed?

Iterum Therapeutics secures key Medicare access for its antibiotic ORLYNVAH™, but a costly FDA trial requirement for a new use casts a shadow on its future.

Anebulo Pharmaceuticals is delisting from Nasdaq to focus on a pediatric cannabis antidote, leaving investors to grapple with an uncertain future.

After a major trial failure tanked its stock, Rezolute pins its hopes on a second drug program and a crucial FDA meeting to chart a path forward.

New data reveals Mesoblast's cell therapy Ryoncil dramatically boosts survival in GvHD patients when used early, paving the way for a major adult trial.

A massive $313M federal funding win brings hope to the ALS community, pushing total investment past $1.6B. But how close are we to a real breakthrough?

NervGen Pharma to unveil data showing its drug NVG-291 provides lasting functional gains for chronic spinal cord injury, a major step forward.

A new deal for the rare isotope Actinium-225 could break a major supply bottleneck, accelerating the development of highly targeted cancer treatments.

Discover how a brand born from cancer research is reshaping skincare with its launch at Ulta Beauty, making advanced biotech formulas accessible to everyone.

FibroBiologics' Pete O'Heeron will speak at the H-SPAN summit, highlighting how cell therapy is driving a push for new healthspan legislation.

The biotech celebrates its first FDA drug approval, a massive financial boost, and promising new therapies targeting obesity and Alzheimer's disease.

VectorY Therapeutics adds seasoned biotech architect Kevin Pojasek to its board, signaling a strategic push to accelerate its novel therapies for ALS and Alzheimer's.

MetaVia's drug vanoglipel gets a major boost from AI modeling, validating its potential to treat complex metabolic diseases like MASH and Type 2 Diabetes.

An expanded partnership aims to deliver a once-daily oral tablet for hypoparathyroidism, potentially revolutionizing treatment for thousands of patients.

Affinia Therapeutics gets the green light for a human trial of AFTX-201, a one-time therapy for a devastating genetic heart disease, BAG3 DCM.

With crucial data on its novel oral inflammation inhibitor looming, NodThera brings in seasoned leader Geoff McDonough to navigate the path to Phase 3.